Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference

Rhea-AI Summary

Cidara Therapeutics (Nasdaq: CDTX) announced it will present preclinical data on CD388 at the ASM Microbe 2024 conference, from June 13-17, 2024, in Atlanta, Georgia. CD388 is a novel Drug-Fc Conjugate (DFC) being developed for influenza prevention, using Cidara's proprietary Cloudbreak® platform. The presentation, led by Dr. Voon Ong, will focus on comparing different allometric scaling approaches to project human pharmacokinetics (PK) of CD388. The session, titled 'AAR07 Saturday Antimicrobial Pharmacokinetics and Pharmacodynamics,' will take place on June 15, 2024, from 10:00 AM to 5:00 PM ET at the Exhibit Hall, poster board number AAR-SATURDAY-494.

Positive

• Cidara Therapeutics is actively developing CD388 for influenza prevention, potentially addressing a significant health need.
• Presentation at ASM Microbe 2024 provides visibility and credibility within the scientific community.
• Utilization of proprietary Cloudbreak® platform indicates innovative approach and potential competitive advantage.

Negative

• Preclinical data means CD388 is still in early stages of development, presenting risks and uncertainties.
• No information on clinical trial timelines or success rates, which can affect investor confidence.
• Potential for high research and development costs without guaranteed commercial success.

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak^® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will be presenting a poster at the American Society for Microbiology (ASM) Microbe 2024 conference to be held June 13-17, 2024 at the Georgia World Congress Center in Atlanta, Georgia.

Presentation details are summarized below:

Abstract Title: Comparison of Different Allometric Scaling Approaches to Project Human Pharmacokinetics (PK) of CD388, a Novel Drug-Fc Conjugate, in Development for Influenza Prevention 
Presenter: Voon Ong, Ph.D.
Session Title: AAR07 Saturday Antimicrobial Pharmacokinetics and Pharmacodynamics
Presentation Location: Exhibit Hall
Date and Time: Saturday, June 15, 2024, 10:00 AM -5:00 PM ET
Poster Board Number: AAR-SATURDAY-494

About Cidara Therapeutics
Cidara is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company’s portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak^® platform targeting oncologic, viral and autoimmune diseases. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com

FAQ

What is Cidara Therapeutics presenting at ASM Microbe 2024?

Cidara Therapeutics is presenting preclinical data on CD388, a novel Drug-Fc Conjugate in development for influenza prevention.

When and where is Cidara Therapeutics presenting the CD388 data?

The presentation will take place on June 15, 2024, from 10:00 AM to 5:00 PM ET at the Exhibit Hall during the ASM Microbe 2024 conference in Atlanta, Georgia.

What is the focus of Cidara Therapeutics' presentation on CD388?

The focus will be on comparing different allometric scaling approaches to project human pharmacokinetics (PK) of CD388.

Who will be presenting the CD388 data for Cidara Therapeutics?

Dr. Voon Ong will be presenting the CD388 data at the ASM Microbe 2024 conference.

What is the significance of CD388 for Cidara Therapeutics?

CD388 is a novel Drug-Fc Conjugate being developed for influenza prevention, potentially offering a new approach to flu prophylaxis.